Estrella Immunopharma (ESLAW) Competitors $0.04 -0.01 (-14.83%) As of 08/21/2025 09:52 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ESLAW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CEROW, CINGW, and CLNNWShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), CERo Therapeutics (CEROW), Cingulate (CINGW), and Clene (CLNNW). These companies are all part of the "biotechnology" industry. Estrella Immunopharma vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity CERo Therapeutics Cingulate Clene Estrella Immunopharma (NASDAQ:ESLAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment. Does the media prefer ESLAW or ATNFW? In the previous week, 180 Life Sciences' average media sentiment score of 1.14 beat Estrella Immunopharma's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Estrella Immunopharma Neutral 180 Life Sciences Positive Is ESLAW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A N/A N/A 180 Life Sciences N/A N/A N/A Which has preferable earnings and valuation, ESLAW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Summary180 Life Sciences beats Estrella Immunopharma on 1 of the 1 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLAW vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$137.10M$5.82B$9.71BDividend YieldN/A3.74%3.84%4.09%P/E RatioN/A3.8830.9025.97Price / SalesN/A4,051.19469.81120.77Price / CashN/A13.1937.1558.38Price / BookN/A46.299.116.37Net IncomeN/A-$90.99M$3.26B$265.56M7 Day PerformanceN/A0.62%1.85%1.71%1 Month PerformanceN/A3.44%4.86%1.05%1 Year PerformanceN/A197.77%31.15%20.94% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAWEstrella ImmunopharmaN/A$0.04-14.8%N/AN/A$0.00N/A0.00N/AGap DownATNFW180 Life SciencesN/A$0.27-16.0%N/A+3,303.8%$0.00N/A0.007Gap UpHigh Trading VolumeSXTPW60 Degrees PharmaceuticalsN/A$0.11flatN/A+64.0%$0.00$641.41K0.002Positive NewsDRTSWAlpha Tau MedicalN/A$0.30+8.5%N/A+64.8%$0.00N/A0.0080APLMWApollomicsN/A$0.02-4.5%N/A+6.0%$0.00N/A0.0059Positive NewsGap DownBCTXWBriaCell TherapeuticsN/A$0.02-14.6%N/A-91.4%$0.00N/A0.008Positive NewsGap DownCDIOWCardio DiagnosticsN/A$0.01+4.4%N/A-69.3%$0.00$19.51K0.007Positive NewsShort Interest ↓CELUWCelularityN/A$0.04-30.1%N/A+109.5%$0.00$54.22M0.00220Positive NewsCEROWCERo TherapeuticsN/A$0.01+14.6%N/AN/A$0.00N/A0.008Gap UpCINGWCingulateN/A$0.05-0.4%N/A-49.5%$0.00N/A0.0020Gap UpCLNNWCleneN/A$0.04+7.4%N/A+5.4%$0.00$286K0.00100Gap Up Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Celularity Competitors CERo Therapeutics Competitors Cingulate Competitors Clene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLAW) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access